Mosunetuzumab Plus Pola-CHP Compared with Pola-R-CHP in Previously Untreated DLBCL: Final Results from a Phase 2 Study
Blood Advances（2025）
Key words
diffuse large B-cell lymphoma,bispecific antibody,mosunetuzumab,T-cell engaging therapy,combination regimens
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined